EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access

Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper

J M Molero García, S Moreno Guillén, F J Rodríguez-Artalejo, J Ruiz-Galiana, R Cantón, P De Lucas Ramos, A García-Botella, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, M C Martín-Delgado und 3 weitere

Revista Española de Quimioterapia · 19.05.2023 · 36 (3) · 223-235

DOI: 10.37201/req/004.2023 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 08.02.2023. Verfasst von J M Molero García und 14 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. C…. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Neuralgia, Postherpetic, Herpes Zoster. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes zoster infection (HZ) is an important public health problem due to its high incidence and frequent complications, especially post-herpetic neuropathy . The incidence of HZ increases with age and is more frequent in immunocompromised patients. It is estimated that at least 60,000 people develop HZ each year in Spain. The usual forms of HZ are so clinically characteristic that they do not usually require microbiological confirmation, which is reserved for cases without cutaneous manifestations or with atypical presentation. There are currently two vaccines approved by the regulatory agencies and marketed in Spain to prevent the onset of HZ and its complications. The first (Zostavax®) was marketed by the company MSD and licensed in Europe in 2006 and is a live attenuated virus vaccine that is administered in a single dose, while the second (Shingrix®) is a recombinant vaccine, marketed in 2017 and requires two doses. While the former cannot be administered to immunocompromised persons, the latter can be prescribed to any group of adults. The criteria for the indication and financing of these vaccines have not been uniform in the various autonomous communities of Spain. These and other aspects of HZ have been discussed by a group of experts from the Illustrious Official College of Physicians of Madrid (ICOMEM) whose criteria and opinions are included in this paper.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes Zoster VaccineNeuralgia, PostherpeticHerpes ZosterAdultHumansHerpesvirus 3, HumanIncidence

Stichwörter der Autor:innen

Herpes zosterImmunocompromised patientsPostherpetic neuralgiaShingrixVaricella-Zoster VirusZostavaxZosterelderlyvaccines

Substanzen

Herpes Zoster Vaccine

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica y Enfermedades Infecciosas del Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBERES. Ciber de Enfermedades Respiratorias. Madrid, Spain. emilio.bouza@gmail.…

Zitieren

APA

Molero García, J. M., Moreno Guillén, S., Rodríguez-Artalejo, F. J., Ruiz-Galiana, J., Cantón, R., De Lucas Ramos, P., García-Botella, A., García-Lledó, A., Hernández-Sampelayo, T., Gómez-Pavón, J., González Del Castillo, J., Martín-Delgado, M. C., Martín Sánchez, F. J., Martínez-Sellés, M., & Bouza, E. (2023). Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper. Revista Española de Quimioterapia, 36(3), 223-235. https://doi.org/10.37201/req/004.2023

Vancouver

Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, et al. Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper. Revista Española de Quimioterapia. 2023;36(3):223-235. doi:10.37201/req/004.2023

BibTeX
@article{MoleroGarca2023,
  author = {Molero García, J M and Moreno Guillén, S and Rodríguez-Artalejo, F J and Ruiz-Galiana, J and Cantón, R and De Lucas Ramos, P and García-Botella, A and García-Lledó, A and Hernández-Sampelayo, T and Gómez-Pavón, J and González Del Castillo, J and Martín-Delgado, M C and Martín Sánchez, F J and Martínez-Sellés, M and Bouza, E},
  title = {Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper},
  journal = {Revista Española de Quimioterapia},
  year = {2023},
  volume = {36},
  number = {3},
  pages = {223--235},
  doi = {10.37201/req/004.2023}
}
Kostenlos starten →